Vermon design and manufacture customized state-of-the art ultrasound transducers for medical and industrial applications. Leveraging our resources, excellence in engineering, independence, and investments, we offer enhanced solutions, and services addressing complex clinical and industrial needs. For over three decades, we have been a pioneer in providing startups, large industrial groups, and research labs with the most innovative and cutting-edge ultrasound imaging solutions. With a team of over 380 skilled experts across France and the United States, we continue to bring customized solutions to our clients, regardless of their size because we can quickly adapt to each client’s needs.
Veracyte
Veracyte is a global diagnostics company that improves patient care by informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. Our extensive biorepositories, immuno-oncology biomarker testing and analytical services help our biopharmaceutical partners to advance their therapeutic discovery, development and commercialization programs.
Veneno Technologies Co. Ltd.
Creating therapeutic Disulfide-Rich Peptides targeting transmembrane proteins including ion channels, GPCRs, and transporters. | Veneno Technologies is a Japan-origin deep-tech biotech company founded in 2020 and built around a proprietary Disulfide-Rich Peptide, or DRP, discovery platform. Based on scientific achievements originating from AIST, the company has established an integrated end-to-end system combining design, screening, functional evaluation, and production of DRPs through its proprietary Veneno Suite and PERISS platform. Veneno aims to create a new peptide modality for targets that have remained difficult to address with conventional small molecules or antibodies. The company’s core strength lies in its ability to translate the intrinsic biological advantages of naturally occurring DRPs into an industrial discovery engine. Because DRPs possess multiple disulfide bonds and a conformationally constrained structure, they can offer high stability, protease resistance, thermal robustness, and strong target selectivity. These properties make DRPs especially attractive for membrane proteins and other challenging target classes where conventional modalities often face limitations in selectivity, penetration, or functional control. Veneno is leveraging this differentiated biology to generate novel therapeutic candidates with the potential to open new mechanisms of action in previously hard-to-drug disease areas. Current Strategic Focus Areas 1) Ri-DRP drug discovery: Veneno is actively advancing Ri-DRP programs in which DRPs are conjugated with radioactive payloads, including alpha-emitting isotopes. By combining the high target selectivity and compact size of DRPs with radiopharmaceutical design, the company aims to enable precise tumor targeting and differentiated payload delivery beyond what is often achievable with conventional antibody-based radioconjugates or small-molecule radiopharmaceuticals. Ri-DRP represents a highly strategic direction for Veneno, particularly in oncology, where target-specific delivery, tissue distribution, and therapeutic precision are central to next-generation drug design. 2) Functional development of DRPs as next-generation antibody-like molecules: Veneno positions DRPs not simply as peptides, but as a next-generation functional modality that can complement and, in selected settings, outperform antibodies. The compact and highly structured nature of DRPs allows precise interaction with biologically important surfaces while maintaining strong stability and selectivity. This creates opportunities in areas where antibodies may be constrained by tissue penetration, epitope accessibility, or molecular size. Veneno is therefore developing DRPs as next-generation antibody-like agents for membrane proteins, complex interaction interfaces, and disease areas that require finely tuned molecular recognition. 3) DRP drug discovery for membrane proteins including ion channels, GPCRs, and transporters: Veneno’s discovery platform is particularly differentiated in the generation of functional DRPs against membrane proteins that have historically been difficult to drug. Through the proprietary PERISS method, the company can identify inhibitor, activator, and binder DRPs for ion channels, GPCRs, transporters, and related membrane targets. These target classes are biologically important across oncology, inflammation, pain, cardiometabolic disorders, and other major therapeutic areas, yet they remain challenging because small molecules can suffer from off-target effects and antibodies often have limited access to the relevant target surfaces. Veneno is using DRPs to bridge this gap and unlock first-in-class opportunities in membrane protein drug discovery. Through these three focus areas, Veneno Technologies is positioning DRPs as a scalable platform for next-generation therapeutics spanning membrane protein drug discovery, antibody-like functional molecules, and radiopharmaceutical innovation. At BIO International 2026, the company is seeking global collaboration opportunities including joint research, co-development, licensing, and strategic partnerships with pharmaceutical companies, biotech innovators, radiopharmaceutical developers, and research institutions.
Veeda Lifesciences
For nearly two decades, Veeda Lifesciences has been a trusted partner in drug development, supporting pharmaceutical, biotech, and specialty healthcare companies in bringing innovative therapies to patients worldwide. Our global presence spans across 9 countries and 26 geographies, allowing us to offer localized expertise while maintaining a broad international reach. By combining scientific excellence, regulatory expertise, and cutting-edge technology, we ensure the execution of efficient, high-quality clinical trials that accelerate the drug development process. A Strategic Partner in Drug Development Veeda Lifesciences partners with innovator companies to navigate the intricate landscape of clinical research and drug development. Our comprehensive suite of services covers: Strategic Consulting: We provide expert guidance in trial design, regulatory pathways, and market access strategies, ensuring seamless progression from preclinical to clinical phases. Regulatory Support: Our regulatory affairs team assists with dossier preparation, regulatory submissions, and interactions with health authorities, streamlining the approval process. Operational Excellence: We offer end-to-end trial management solutions, including site selection, patient recruitment, monitoring, data management, and biostatistical analysis. Expertise Across Multiple Therapeutic Areas With deep domain expertise in key therapeutic areas, Veeda has played a pivotal role in advancing clinical research in: Oncology & Hematology: Our contributions include supporting one of the largest global multiple myeloma trials across 24 countries. By leveraging AI-driven patient recruitment strategies and real-world data, we optimize site selection and accelerate trial timelines. Dermatology: We have successfully executed clinical trials for novel dermatological therapies, addressing conditions such as psoriasis, atopic dermatitis, and skin cancers. Endocrinology & Metabolic Disorders: Veeda has been instrumental in conducting trials for diabetes, obesity, and other endocrine disorders, ensuring the safety and efficacy of new treatment modalities. Other Specialties: Our expertise extends to cardiovascular diseases, infectious diseases, autoimmune disorders, and rare diseases, enabling comprehensive clinical research solutions across various indications. Comprehensive Clinical Development Lifecycle Support Veeda Lifesciences offers integrated solutions across the entire clinical development lifecycle, ensuring scientific rigor, regulatory compliance, and operational efficiency at every stage: Early-Phase Studies: First-in-Human (FIH) and Phase I trials Bioavailability & bioequivalence (BA/BE) studies Pharmacokinetics (PK) and pharmacodynamics (PD) evaluations Adaptive trial designs to optimize early-stage decision-making Late-Stage Clinical Trials: Phase II-IV multi-regional clinical trials (MRCTs) Patient-centric study designs incorporating decentralized trial models Site feasibility assessments and accelerated patient enrollment strategies Global regulatory submissions and post-marketing surveillance Advanced Capabilities and Technology-Driven Approach Our commitment to technological innovation enhances trial efficiency and data integrity through: Bioanalytical Research & Central Lab Services: High-quality analytical testing for small molecules, biologics, and biosimilars, ensuring accurate pharmacokinetic and immunogenicity assessments. Digital Trial Management: AI-powered platforms for real-time data capture, electronic trial management, and remote monitoring, optimizing trial workflows. Patient Engagement Solutions: Digital tools to enhance patient retention, adherence, and real-world evidence generation, improving trial outcomes. Pharmacovigilance & Safety Monitoring: Comprehensive adverse event reporting and risk mitigation strategies, ensuring regulatory compliance and patient safety. Biopharmaceutical Development Expertise Veeda Lifesciences offers a comprehensive suite of services tailored to support the development of biopharmaceuticals, including biologics and biosimilars. Our expertise encompasses non-clinical testing solutions designed to ensure safety, efficacy, and regulatory compliance for complex biological therapies. Key Biopharma Services: Preclinical Research: We conduct rigorous preclinical studies to assess the safety and biological activity of biotherapeutic candidates, providing a solid foundation for clinical development. Bioanalytical Support: Our bioanalytical services include method development, validation, and high-throughput sample analysis, delivering precise data essential for regulatory submissions. Regulatory Consulting: We offer strategic guidance on regulatory pathways for biologics and biosimilars, assisting with dossier preparation and interactions with health authorities to streamline approvals. By integrating these services, Veeda Lifesciences ensures a seamless transition from discovery to market for biopharmaceutical products, upholding the highest standards of scientific integrity and patient safety. Beyond Clinical Trials: Integrated Research Solutions Veeda Lifesciences offers a holistic approach to drug development with a diverse range of research services, including: Preclinical Testing: In vitro and in vivo studies to assess drug safety, efficacy, and toxicity before clinical trials. Regulatory Consulting: Expert navigation of global regulatory landscapes, including US FDA, EMA, MHRA, DCGI, and other health authorities. Medical Writing & Scientific Documentation: Preparation of clinical study reports, investigator brochures, regulatory dossiers, and scientific publications to support regulatory approvals. A Trusted Partner for Advancing Life-Changing Therapies Veeda Lifesciences is committed to upholding the highest standards of scientific integrity, patient-centric research, and global regulatory excellence. Our collaborative approach, coupled with a strong emphasis on quality, innovation, and operational efficiency, makes us the preferred partner for companies seeking to bring transformative therapies to market. For more information, visit: Veeda Lifesciences
Varex Imaging
For 75 years Varex has created innovative, high-quality components for X-ray imaging systems, collaborating with our customers to create products that positively impact the lives of millions of people every day. | Varex Imaging Corporation is the world’s largest independent supplier of X-ray tubes, X-ray detectors, high-voltage cables/connectors, AECs, and software solutions . Our components are used by X-ray imaging system manufacturers everywhere to detect, diagnose, and protect. Our cutting-edge technology includes photon counting, multi-beam X-ray, and AI-enhanced software from MeVis diagnostic, showcasing Varex’s innovative solutions. As a leader in imaging components, we aim to help our customers become world-class system suppliers by strengthening their competitiveness and enabling them to bring products to market faster. With over 75 years of dedication to the imaging industry, our rich history is a testament to our commitment. However, our everyday work is devoted to our partners’ success.
Valpharma International S.p.A.
Valpharma Group SpA is an European pharmaceutical company leader in pharmaceutical development and contract manufacturing of oral FDF solid dosage medicines and nutraceuticals, with more than 45 years expertise in commercial supply in more than 70 markets. Our plants are authorized to manufacture (IMP and commercial) powders, granulates, film-coated- not film-coated tablets (FDF), pellets bulk or capsules (FDF). Dossiers: Melatonine ER Apixaban IR Gliclazide SR Diltiazem SR In development Semaglutide IR Upadacitinib ER Mirabegron ER
Valerian Chem Private Ltd
VProteomics, Valerian Chem Pvt. Ltd. to Showcase Advanced Mass Spectrometry Solutions at BIO International Convention 2025 We are excited to announce that VProteomics, Valerian Chem Pvt. Ltd. will be participating in the Innovative India Pavilion at the BIO International Convention 2025, taking place from June 16–19, 2025, at the Boston Convention & Exhibition Center, USA. As a leading provider of high-end mass spectrometry services, VProteomics specializes in proteomics, metabolomics, and clinical diagnostics, catering to academic institutions, medical researchers, and pharmaceutical companies. Our state-of-the-art laboratory in Noida is equipped with the latest mass spectrometry infrastructure, enabling us to deliver precise and reproducible results. Our Core Competencies: Discovery & Targeted Proteomics: Comprehensive protein analysis to elucidate complex biological processes. Advanced Metabolomics: In-depth metabolite profiling to understand metabolic pathways and disease mechanisms. Clinical Mass Spectrometry: Diagnostic services including biomarker detection, enzyme analysis, and toxicology testing, facilitating early disease diagnosis and personalized medicine. Biologics Characterization: Detailed analysis of biologic therapeutics to ensure efficacy and safety. We invite our esteemed clients, collaborators, and partners to visit our booth at the Innovative India Pavilion to explore potential collaborations and learn more about our contributions to the global biotech landscape. Event Details: Event: BIO International Convention 2025 Dates: June 16–19, 2025 Location: Boston Convention & Exhibition Center, Boston, USA Pavilion: Innovative India Pavilion For more information about our services, please visit our website: www.vproteomics.com We look forward to connecting with you in Boston!
VacuTec Messtechnik GmbH
Manufacturer of Dose Area Product Meters (DAP-meters, VacuDAP) and Automatic Exposure control sensors (AEC chambers) for Diagnostic X-ray systems. Manufacturer of Ionisation chambers for Isotope Calbrators in Nuclear Medicine.
UNLV Office of Technology Transfer and Economic Development
UNLV is Nevada’s premier public research university and a powerhouse for groundbreaking discovery and innovation, particularly in life sciences and biotechnology. At the forefront of UNLV’s industry and business engagement are our dynamic offices of Economic Development and Technology Transfer, serving as vital connectors between pioneering research and impactful commercialization opportunities. UNLV’s cutting-edge Brain Health Department as well as the innovative Wastewater Surveillance Laboratory exemplify our bold approach to solving complex health and environmental challenges. Researchers at these centers drive groundbreaking advancements with profound implications for neuroscience, public health, environmental monitoring, and disease prevention. Uniquely situated within a collaborative and vibrant regional ecosystem, UNLV thrives alongside major stakeholders committed to ambitious, strategic coordination and innovative thinking. This environment enables business and industry partnerships to flourish, supported by open communication and outside-the-box planning that accelerate shared success. At BIO International 2025, our goal is clear: to connect industry leaders, visionaries, and partners directly with UNLV’s exceptional talent, transformative research capabilities, and rich pipeline of licensable technologies. Opportunities abound at UNLV for collaborative sponsored research, tailored workforce development programs, robust startup incubation support, and access to patented university technologies poised for commercialization. Discover how partnering with UNLV can propel your organization’s priorities forward through innovative solutions and collaborations. Connect with us at BIO to harness the full potential of our research excellence and vibrant innovation ecosystem. | UNLV, a Carnegie R1 research institution, is a key player in the delegation’s efforts. UNLV emphasizes industry engagement through opportunities for students, strong bio research, innovation, a collaborative research and technology park, and commercialization of life-changing products in fields like life science, physical science, and engineering. UNLV is seeking to connect with BIOtech companies and explore collaboration opportunities.